ReviewMolecules (Basel, Switzerland)2025
The Role of Genistein in Type 2 Diabetes and Beyond: Mechanisms and Therapeutic Potential.
Review in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Potential Role of Polyphenols in Platelet Aggregation and Blood Coagulation.Journal of cardiovascular development and disease · 2026Review
- Genistein in polycystic ovary syndrome: mechanisms, preclinical evidence, and translational potential.Frontiers in global women's health · 2026Review
- Effects of Genistein on Inflammasome Induced Pancreatic β-Cell Apoptosis by Dexamethasone.Molecular nutrition & food research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The global prevalence of type 2 diabetes mellitus (T2DM) necessitates the exploration of novel therapeutic approaches to mitigate its complex molecular pathogenesis. This review investigates the potential role of genistein, a prominent isoflavone derived from soybeans, in the management of T2DM. Recognized for its selective estrogen receptor modulator (SERM) activity, genistein exerts a multifaceted influence on key intracellular signaling pathways, which are crucial in regulating cell proliferation, apoptosis, and insulin signaling. Genistein's anti-inflammatory, anti-oxidant, and metabolic regulatory properties position it as a promising candidate for T2DM intervention. This review synthesizes current research spanning preclinical studies and clinical trials, emphasizing genistein's impact on insulin sensitivity, glucose metabolism, and inflammatory markers. Additionally, this review addresses genistein's bioavailability, safety, and potential influence on gut microbiota composition. By consolidating these findings, this review aims to provide a comprehensive understanding of genistein's therapeutic potential in T2DM management, offering valuable insights for future research and clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.